SynthesisPloS one2025
Utility of cochlear perilymph biomarkers for hearing loss - A systematic review.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Therapeutic Timing at Mitochondrial Redox-Autophagy-Mitophagy Checkpoints in Age-Related Hearing Loss.Molecular neurobiology · 2026Review
- The inner ear immune microenvironment in sensorineural hearing loss: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- Cochlear neural functional competence: an integrative transcriptomic module analysis of excitability, plasticity and microenvironmental support programs.Frontiers in cellular neuroscience · 2026Article
- Targeting ferroptosis in sensorineural hearing loss: mechanisms, therapeutics, and translational prospects.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The live cochlea is a critical and delicate sensory organ with tissue sampling posing a risk to balance and hearing functions. Consequently, a researchers' ability to investigate the pathogenesis of sensorineural hearing loss (SNHL) has been limited, commonly involving in vitro models, translational animal models and post-mortem analysis. Previous human studies investigating SNHL have primarily been restricted to using peripheral blood or cerebrospinal fluid samples that indirectly measure inner ear pathologies. More recently, the establishment of a novel, safe, and feasible technique for intraoperative perilymph sampling has enabled the collection of a 'liquid biopsy' of the cochlea whilst still preserving inner ear function. This crucial development has opened avenues for characterising the cochlea microenvironment and subsequently investigating the mechanisms of SNHL. Perilymph sampling may also provide insights into why postoperative outcomes vary between cochlear implant users with otherwise similar preoperative clinical characteristics. The present systematic review aimed to elucidate the gap in the literature regarding the utility of perilymph biomarkers in SNHL diagnosis, treatment, and prognosis. Medline, Embase, Web of Science, and Scopus were searched for two groups of keywords related to 'biomarker' and 'SNHL'. Of the 7471 studies initially identified, 15 met the inclusion criteria. Based on the findings of these studies, biomarkers were grouped into six main categories based on their underlying pathological processes: heat shock proteins (HSP), immune-related, microRNA, neurotrophic, metabolome, and structural. For each category, this review identifies potential biomarkers that should be carefully validated in future studies. In particular, HSP70 and HSP90, complement components, mi1299, mi1270, and brain-derived neurotrophic factor regulated proteins may help direct future studies focused on characterising the biomarker profile in patients with SNHL. Future studies should ideally also utilise larger cohorts of patients with specified hearing loss aetiologies. Such studies may help to pave the way towards a more accurate diagnosis of SNHL, improved prediction of cochlear implantation prognosis, and targeted therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.